期刊
CLINICAL MICROBIOLOGY AND INFECTION
卷 28, 期 8, 页码 1044-1046出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.cmi.2022.03.030
关键词
Antivirals; COVID-19; Drug safety; Drug-drug interactions; Nirmatrelvir; Ritonavir; Pharmacokinetic boosters